We are a liver cancer and regeneration research group at Hannover Medical School AG-Vogel/AG-Saborowski @ArndtVogel @SaborowskiAnna
Hannover, Germany
Joined April 2021
- Tweets74
- Following531
- Followers302
- Likes137
Liver Cancer Lab retweeted
Good morning Barcelona!
Looking forward to day second of #WCGIC2022
Starting off with challenging #HCC cases with @DucreuxMichel @GABOUALFA Bruno Sangro Rene Adams and Thierry de Baere
Liver Cancer Lab retweeted
New #immunotherapy kids on the block for advanced #CRC?
Very promising data presented #WCGCI2022
Botensilimab and Balstilimab —> Fc enhanced CTLA4/PD1 combination
Compelling ORR of 24%
Is there a role of liver mets for IO efficacy?
@myESMO @OncoAlert
Liver Cancer Lab retweeted
Looking forward to a great symposium on #PrecisionMedicine in #cholangiocarcinoma
👉join us 13:00 at #WCGIC2022 to discuss targeted therapies with #JohnBridgewater #EricvanCutsem @LorenzaRimassa
@myESMO @enscca
Liver Cancer Lab retweeted
Super proud of my colleague @ArndtVogel for presenting the final analysis of the practice changing Fight-202 trial for pts with FGFR2 altered #cholangiocarcinoma at #WCGIC2022 #livertwitter
Liver Cancer Lab retweeted
1. BRAF V600E is a very important target in melanoma and non-melanoma solid tumors 👉 Recent papers in @CD_AACR @TheLancetOncol @NEJM #JCO @ASCO_pubs @CSHL @trendscancer @CellCellPress & important BRAF papers tweetorial. #WeekendSpecial cell.com/trends/cancer/fullt…
Liver Cancer Lab retweeted
👏Comprehensive review on BRAF V600E
doi: 10.1158/1535-7163.MCT-21-0950
👉detected in > 40 cancer types
👉BRAF inhibition effective > 20 cancer types
👉RWD in 69 cancer types
👉BRAFi/MEKi > BRAFi , but CRC + EGFRi
👉9 FDA approvals, now tumor-agnostic
@OncoAlert @myESMO
Liver Cancer Lab retweeted
👏Understanding evolution of resistance to targeted therapy
doi.org/10.1038/s41587-020-0….
❓selection or de novo acquisition?
👉CaTCH: method to analyze founder clones their postselection counterparts
Proof of concept for RAFi/MEKi resistance
#precisionmedicine
Liver Cancer Lab retweeted
#WCGIC2022 #Youngoncologist sessions: 'ESMO Session: Focus on Young Oncologists, with #ESMOYOC', plus finding local & intl. mentors to build your career, #Gendermedicine in #GItumours, disparities in access to new drugs 👇
🔗 ow.ly/SEoF50JIiES
@ESMOWorldGI #GIcancer
Liver Cancer Lab retweeted
💊💊Critical appraisal of FDA approvals: food for thoughts!
doi.org/10.1038/s41571-022-0…
👉 71 2002-14
👉161 2017-21
👉71 IO 💉
👉 62 small molecules💊
👉 5 T-agnostic
✅ 47 with OS
❗️ 58 with ORR
❗️ 39 with PFS
❗️only 42 with subs. benefit acc.ESMO-MCBS
@myESMO #Immunotherapy
Liver Cancer Lab retweeted
Watch on demand: today's tumor heterogeneity symposium #ILC2022 with @Valeriechew29 from 🇸🇬:
⬆️immune intratumoral heterogeneity is associated with
⬆️immunosuppressive tumor microenvironment and
⬇️clinical outcome parameters in #HCC
👉nature.com/articles/s41467-0…
#LiverTwitter
Liver Cancer Lab retweeted
EASL YI task force preparing for the YI Seminar tomorrow at 08:00 sharp😀. Make sure to join us there, early birds 🦆 @EASLedu #LiverTwitter #ILC2022
Liver Cancer Lab retweeted
Hurry up or you will miss Heiner Wedemeyer‘s Talk in the YI Symposium ! Capital Suite 17! Now! No excuses! #ILC2022
Liver Cancer Lab retweeted
Entertaining and informative talk by H. Wedemeyer
➡️history of discoveries of hepatitis viruses
➡️landmark publications and their
➡️impact on hepatitis treatment strategies
A grand start to the YI Symposium ⭐️(And I am NOT saying this bc he is my boss…)
Liver Cancer Lab retweeted
This is EXACTLY what we aimed for when preparing the yi symposium: excellent speakers that take us on a journey 🧭through their field, highlighting novel developments but also dead ends. Thank you @analleo for your insights and advice!#ILC2022 #LiverTwitter
Liver Cancer Lab retweeted
Future of metabol. liver disease research: key insights from M. Vacca:
❗️Stop using 2D cultures for metabolic studies, go for precision cut liver slices
❗️multi organ on chip and
❗️advanced natural ecm organoids is what we should aim for
‼️Consensus on preclin. models are key!
Liver Cancer Lab retweeted
🔥FGFR2 alterations in #cholangiocarcinoma
👉fusion: FGFR2 intron 17/exon 18 breakpoint; partner is known or novel/in-frame with FGFR2
👉rearrangement: gene is out-of-frame with ex. 17
👉truncation: loss of neg. regulatory element
👉In-Frame Deletion..
✅all druggable
@myESMO
Liver Cancer Lab retweeted
🔥concerning data on acetaminophen for #immunotherapy @JCO_ASCO
doi.org/10.1016/j.annonc.202…
👉APAP --> Treg⬆️ --> IO efficacy⬇️: ORR, PFS, OS
❗️be aware of concomitant💊💊:statins, steroids, antibiotics, proton-pump inhibitors...
@OncoAlert @myESMO
Liver Cancer Lab retweeted
👏Excellent summary on Hyperprogression and #Immunotherapy in @trendscancer
doi.org/10.1016/j.trecan.202…
👉no clear definition, only retros. data
👉no biomarker
❓role of TME
✅clear need to identify patients with devastating outcome on ICI
@OncoAlert, @myESMO
Liver Cancer Lab retweeted
YI Paula Olaizola presenting her comprehensive work on the role of NEDDylation in #cholangiocarcinoma in the abstract session
➡️targeting NEDDylation pharmacologically or genetically impacts tumor growth in vitro & in vivo
👏to new takes on CCA!
#LiverTwitter #ILC2022
